1. Home
  2. BYFC vs IGMS Comparison

BYFC vs IGMS Comparison

Compare BYFC & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BYFC
  • IGMS
  • Stock Information
  • Founded
  • BYFC 1946
  • IGMS 1993
  • Country
  • BYFC United States
  • IGMS United States
  • Employees
  • BYFC N/A
  • IGMS N/A
  • Industry
  • BYFC Savings Institutions
  • IGMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BYFC Finance
  • IGMS Health Care
  • Exchange
  • BYFC Nasdaq
  • IGMS Nasdaq
  • Market Cap
  • BYFC 70.3M
  • IGMS 81.9M
  • IPO Year
  • BYFC 1996
  • IGMS 2019
  • Fundamental
  • Price
  • BYFC $8.05
  • IGMS $1.28
  • Analyst Decision
  • BYFC
  • IGMS Hold
  • Analyst Count
  • BYFC 0
  • IGMS 8
  • Target Price
  • BYFC N/A
  • IGMS $6.00
  • AVG Volume (30 Days)
  • BYFC 7.4K
  • IGMS 542.3K
  • Earning Date
  • BYFC 07-31-2025
  • IGMS 08-13-2025
  • Dividend Yield
  • BYFC N/A
  • IGMS N/A
  • EPS Growth
  • BYFC N/A
  • IGMS N/A
  • EPS
  • BYFC N/A
  • IGMS N/A
  • Revenue
  • BYFC $32,659,753.00
  • IGMS $145,050,000.00
  • Revenue This Year
  • BYFC N/A
  • IGMS $252.44
  • Revenue Next Year
  • BYFC N/A
  • IGMS $46.48
  • P/E Ratio
  • BYFC N/A
  • IGMS N/A
  • Revenue Growth
  • BYFC N/A
  • IGMS 4882.82
  • 52 Week Low
  • BYFC $4.86
  • IGMS $0.92
  • 52 Week High
  • BYFC $9.46
  • IGMS $22.50
  • Technical
  • Relative Strength Index (RSI)
  • BYFC 59.30
  • IGMS 50.36
  • Support Level
  • BYFC $7.76
  • IGMS $1.25
  • Resistance Level
  • BYFC $8.85
  • IGMS $1.33
  • Average True Range (ATR)
  • BYFC 0.27
  • IGMS 0.02
  • MACD
  • BYFC -0.05
  • IGMS -0.00
  • Stochastic Oscillator
  • BYFC 29.82
  • IGMS 37.50

About BYFC Broadway Financial Corporation

Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.

About IGMS IGM Biosciences Inc.

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Share on Social Networks: